Medical Maggots and Leeches in Modern NHS Practice: Indications, Regulation, and Evidence

Biotherapy in the 21st Century NHS

Both are licensed medicinal products (MHRA), used in specialized centers under strict protocols.

Maggot Debridement Therapy (MDT)

  • Agent: Lucilia sericata (green bottle fly) larvae, sterile, medical-grade.
  • Mechanism: Debridement (proteolytic enzymes), disinfection (antimicrobial peptides), angiogenesis (growth factors).
  • Indications: Chronic wounds (diabetic foot, venous leg, pressure ulcers), necrotic tissue, MRSA-colonized wounds failing standard care.
  • Protocol: Biobag (contained) or free-range; 48–72 hrs; repeat q1–2 wks. Requires moist wound bed.
  • Evidence: RCTs show faster debridement vs. hydrogel; healing equivalence. NICE MTG17 supports use.
  • Barriers: Patient/staff aversion, cost (~£200–300/treatment), logistics.

Hirudotherapy (Leech Therapy)

  • Agent: Hirudo medicinalis, farmed sterile.
  • Mechanism: Hirudin (thrombin inhibitor), calin, hyaluronidase → anticoagulation, vasodilation, venous decongestion.
  • Indications: Venous congestion in replantation (fingers, ears, scalp), free flaps, hematoma evacuation.
  • Protocol: 1–10 leeches × 6–12 hrs; monitor Hb, transfusion trigger. Antibiotic prophylaxis (Aeromonas—ciprofloxacin/TMP-SMX).
  • Evidence: Case series/cohort studies; standard of care in microsurgery units. NICE IPG199.

Governance

  • MDT/Hirudotherapy leads in wound/microsurgery units.
  • Patient consent (specific for biotherapy).
  • Pharmacy procurement, controlled storage, waste disposal (leech euthanasia).
  • Incident reporting (escape, allergic reaction).

Not first-line. Reserved for specialist decision when conventional options exhausted.

Folk Medicine - Related Articles